Lupo E, Locher R, Weisser B, Vetter W
University Hospital of Zürich, Switzerland.
Biochem Biophys Res Commun. 1994 Sep 30;203(3):1803-8. doi: 10.1006/bbrc.1994.2396.
The dose-dependent (1, 5, 10, 50 microM) antioxidative activity of calcium antagonists (verapamil, diltiazem, nifedipine, amlodipine, isradipine or lacidipine) and alpha-tocopherol against copper-induced LDL (0.25 mg/ml) oxidation was compared by measuring the diene formation and the content of TBARS. For diltiazem no antioxidant effect could be found, whereas the other calcium antagonists and alpha-tocopherol have demonstrated antioxidant activity at least at concentrations of 10 and 50 microM: alpha-tocopherol > lacidipine > nifedipine > isradipine, verapamil, amlodipine. Additionally, alpha-tocopherol and lacidipine were able to attenuate LDL-oxidation significantly at 1 and 5 microM. These results indicate in vitro antioxidative activity of calcium antagonists especially from the dihydropyridine-type with greatest activity for the strongly lipophilic lacidipine. This might be one possible antiatherogenic mechanism of calcium antagonists, since oxidative modification enhances the atherogenic potential of LDL.
通过测量二烯生成量和硫代巴比妥酸反应物(TBARS)含量,比较了钙拮抗剂(维拉帕米、地尔硫䓬、硝苯地平、氨氯地平、伊拉地平或拉西地平)和α-生育酚在剂量依赖(1、5、10、50微摩尔)情况下对铜诱导的低密度脂蛋白(LDL,0.25毫克/毫升)氧化的抗氧化活性。地尔硫䓬未发现抗氧化作用,而其他钙拮抗剂和α-生育酚至少在10和50微摩尔浓度时表现出抗氧化活性:α-生育酚>拉西地平>硝苯地平>伊拉地平、维拉帕米、氨氯地平。此外,α-生育酚和拉西地平在1和5微摩尔时能够显著减弱LDL氧化。这些结果表明钙拮抗剂具有体外抗氧化活性,尤其是二氢吡啶类,其中亲脂性强的拉西地平活性最高。这可能是钙拮抗剂的一种抗动脉粥样硬化机制,因为氧化修饰会增强LDL的动脉粥样硬化潜力。